| 1 |
34515877 | Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. | 2022 Feb |
1 |
| 2 |
35142863 | A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies. | 2022 Mar |
1 |
| 3 |
33860036 | Cediranib Induces Apoptosis, G1 Phase Cell Cycle Arrest, and Autophagy in Non-Small-Cell Lung Cancer Cell A549 In Vitro. | 2021 |
2 |
| 4 |
29925934 | Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. | 2018 Jul |
1 |
| 5 |
28559461 | The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer. | 2017 Sep 15 |
1 |
| 6 |
26420897 | Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature. | 2016 May |
1 |
| 7 |
26929887 | Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine. | 2016 Jan 16 |
1 |
| 8 |
25329007 | A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. | 2015 Jul |
2 |
| 9 |
25676691 | VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner. | 2015 Apr 28 |
2 |
| 10 |
26008604 | A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. | 2015 Oct |
2 |
| 11 |
26179332 | Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer. | 2015 Sep |
3 |
| 12 |
26188774 | A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. | 2015 Sep |
1 |
| 13 |
24788563 | A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. | 2014 Oct |
1 |
| 14 |
24850841 | VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. | 2014 Jul 15 |
1 |
| 15 |
24927771 | Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis. | 2014 Sep |
1 |
| 16 |
25218906 | Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. | 2014 Oct |
1 |
| 17 |
23630200 | Cediranib for metastatic alveolar soft part sarcoma. | 2013 Jun 20 |
1 |
| 18 |
24640739 | [VEGFRs in neoplastic angiogenesis and prospects for therapy of brain tumors]. | 2013 |
1 |
| 19 |
22297207 | Beyond bevacizumab: antiangiogenic agents. | 2012 Sep |
2 |
| 20 |
22476055 | Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma. | 2012 May 1 |
1 |
| 21 |
22572725 | Antiangiogenic approaches for the treatment of advanced synovial sarcomas. | 2012 Jul |
2 |
| 22 |
22859418 | Kidney injury during VEGF inhibitor therapy. | 2012 Aug |
1 |
| 23 |
20061136 | Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. | 2010 Mar |
3 |
| 24 |
19215823 | The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts. | 2009 Mar 1 |
3 |
| 25 |
19308410 | Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. | 2009 Nov |
2 |
| 26 |
19755510 | Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. | 2009 Sep |
2 |
| 27 |
19826113 | Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. | 2009 Nov 20 |
1 |
| 28 |
17457854 | Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. | 2008 Mar |
1 |
| 29 |
18559522 | The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. | 2008 Jun 15 |
4 |
| 30 |
19007739 | Novel anti-angiogenic therapies for malignant gliomas. | 2008 Dec |
1 |
| 31 |
17671138 | The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. | 2007 Aug 1 |
2 |
| 32 |
17671152 | Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. | 2007 Aug 1 |
1 |
| 33 |
17699717 | Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. | 2007 Aug |
6 |
| 34 |
18320010 | Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor. | 2007 |
1 |
| 35 |
15899831 | AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. | 2005 May 15 |
3 |